A Phase II, Open Label, Multicenter Randomised Controlled Trial Comparing Hyperthermia Plus Mitomycin To Mitomycin Alone, In Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

Queen Mary University of London (UK)0 个研究点目标入组 259 人开始时间: 2014年4月17日最近更新: 2024年3月18日

适应症

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35999119/ (added 24/08/2022)

•1. New or Recurrence of intermediate risk NMIBC following TURBT defined as;
•1.1.Grade 2 or grade 1 stage Ta or T1 disease*.
•1.2. Any grade G2 or G1 recurrent bladder cancer other than low-risk and muscle-invasive disease
•2. Age = 18 years
•3. WHO performance status 0, 1, 2, 3
•4. Normal kidneys and ureters on imaging study within the past 12 months**
•5. Pre-treatment haematology and biochemistry values within acceptable limits:
•5.1. Haemoglobin (greater than or equal to)10 g/dl
•5.2. Neutrophil count (Greater than or equal to)1.5 x 10^9/l
•5.3. Platelets (Greater than or equal to) 100 x 10^9/l
•5.4. WBC (Greater than or equal to) 3.0 X 10^9/l or ANC greater than or equal to 1.5 X 10^9/l
•5.5. Serum creatinine < 1.5 X UNL
•6. Negative pregnancy test for women of childbearing potential.
•7. Available for longterm followup.
•8. Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
•9. Written informed consent.
•*T1 disease must have evidence of muscle in specimen. If muscularis propria is not present, a reresection should be performed (accordance with National best practice policy)
•**Imaging of upper tracts by CT or US scan is routinely performed in some centres and is recommended as good practice in this study
•Target Gender: Male & Female ; Lower Age Limit 18 years

•1. Grade 3 TCC
•2. Carcinoma in situ
•3. New solitary Ta G1 (Small)<3cm
•4. New solitary Ta G2 (Small)<3cm
•5. Previous intravesical chemotherapy in the past 6 months, other than single instillation postTUR.
•6. History of limited vesicle capacity (<200cc)
•7. UCC involving the prostatic urethra or upper urinary tract.
•8. Greater than or equal to T2 UCC
•9. Known allergy to mitomycin
•10. Pregnant or lactating women or women of childbearing potential unwilling or unable to use adequate nonhormonal contraception.
•11. Other malignancy within the past five years, except: non-melanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix or DCIS/LCIS of the breast or prostate cancer with less than 5yrs life expectancy.
•12. Concurrent chemotherapy.

发起方

Queen Mary University of London (UK)